What are the suitability criteria and comparisons for Neomycin, Polymyxin B, and Hydrocortisone (corticosteroid) otic suspension, Neomycin, Polymyxin B, and Fluocinolone (corticosteroid) otic suspension, and Ofloxacin (fluoroquinolone antibiotic) 0.3% otic solution in treating acute otitis externa?

ESSC Table for Acute Otitis Externa: Comparison of Three Topical Preparations

Suitability Criteria for Topical Therapy in Acute Otitis Externa

All three preparations are appropriate first-line options for uncomplicated acute otitis externa, but ofloxacin is the only safe choice when tympanic membrane integrity is uncertain or compromised. 1, 2

General Inclusion Criteria (All Three Agents):

• Clinical diagnosis of acute otitis externa with ear canal inflammation, tenderness, edema, and/or discharge 1, 2
• Age ≥6 months for ofloxacin; age ≥2 years for neomycin/polymyxin B combinations (inadequate safety data under age 2) 3, 4
• Intact tympanic membrane confirmed on examination (for neomycin-containing preparations only) 2, 4
• Diffuse, uncomplicated infection without extension beyond the ear canal 1, 2

Critical Exclusion Criteria:

• Perforated tympanic membrane or tympanostomy tubes (absolute contraindication for neomycin/polymyxin B preparations due to ototoxicity risk) 2, 3
• Known hypersensitivity to neomycin (affects 5-15% of patients with chronic external otitis; 13% of normal volunteers show hypersensitivity on patch testing) 1
• History of contact dermatitis to topical antibiotics or vehicle substances 1, 2
• Extension of infection beyond ear canal (requires systemic antibiotics in addition to topical therapy) 1, 2

---

Comparative Table: Three Topical Preparations for Acute Otitis Externa

Criterion	Neomycin/Polymyxin B/Hydrocortisone	Neomycin/Polymyxin B/Fluocinolone	Ofloxacin 0.3%
FDA Approval Status	Approved for otitis externa [4]	Approved for otitis externa	Approved for otitis externa (age ≥6 months), chronic suppurative otitis media, and acute otitis media with tubes [3]
Tympanic Membrane Status	INTACT ONLY - ototoxic if membrane perforated [2,4]	INTACT ONLY - ototoxic if membrane perforated [2]	Safe with perforation or tubes - non-ototoxic [2,3,5]
Minimum Age	≥2 years (inadequate data <2 years) [4]	≥2 years (inadequate data <2 years)	≥6 months [3,6]
Dosing Frequency	3-4 drops 4 times daily for 7-10 days [5,7]	3-4 drops 4 times daily for 7-10 days	5 drops (children) or 10 drops (adults) once daily for 7 days [6,7]
Clinical Cure Rate	83.9-94.7% [7,8]	Similar to hydrocortisone formulation	90.9-95% [6,7,8]
Bacterial Eradication	86.0-97.1% (declining with emerging resistance) [7,9]	Similar to hydrocortisone formulation	94.7-98% [7,8,9]
Antimicrobial Spectrum	Polymyxin B (gram-negative), Neomycin (gram-positive/negative) - resistance increasing [9]	Polymyxin B (gram-negative), Neomycin (gram-positive/negative) - resistance increasing [9]	Broad fluoroquinolone coverage including P. aeruginosa (98% eradication) and S. aureus - no resistance trend [5,6,9]
Steroid Component	Hydrocortisone 1.0% - contact sensitivity in 13-30% of chronic cases [1,2]	Fluocinolone (more potent corticosteroid)	None - effective pain relief without steroids [7]
Pain Relief	Rapid (within 48-72 hours); steroid hastens relief [2,7]	Rapid (within 48-72 hours); steroid hastens relief [2]	Rapid and comparable to steroid-containing preparations (within 48-72 hours) [7]
Ototoxicity Risk	YES - aminoglycoside ototoxicity if membrane compromised [2,5,7]	YES - aminoglycoside ototoxicity if membrane compromised [2]	NO - not ototoxic in animal or human studies [5,7]
Contact Dermatitis Risk	HIGH - neomycin causes reactions in 5-15% of patients [1,2]	HIGH - neomycin causes reactions in 5-15%; hydrocortisone sensitivity in 13-30% [1,2]	LOW - pruritus in 2-7%, application site reactions in 3-5% [10,5]
Adverse Events	Similar overall rate to ofloxacin; contact allergy common [5,7]	Similar to hydrocortisone formulation; potential for prolonged steroid effects	Pruritus (5-7%), bitter taste (5%), application site reactions (4-5%) [10,5]
Compliance	Lower - 4 times daily dosing [7]	Lower - 4 times daily dosing	Higher - once daily dosing (98% adherence) [6]
Duration of Therapy	7-10 days (not >10 days to avoid fungal overgrowth) [4]	7-10 days (not >10 days to avoid fungal overgrowth)	7 days (68% cured within 7 days) [6]
Resistance Trends	Increasing - MICs for neomycin and polymyxin B rose above breakpoints in recent studies [9]	Increasing - MICs for neomycin and polymyxin B rose above breakpoints in recent studies [9]	Stable - MICs remain within susceptible range over time [9]
Cost Consideration	Generally less expensive	Generally less expensive	Generally more expensive but offset by once-daily dosing

---

Key Clinical Decision Points

When Tympanic Membrane Integrity is Uncertain or Compromised:

• Use ONLY ofloxacin 0.3% - this is the only non-ototoxic option and the only FDA-approved agent for perforated membranes or tympanostomy tubes 2, 3, 5

When Tympanic Membrane is Definitively Intact:

• All three options are acceptable, but consider: 1, 2
  • Ofloxacin advantages: Once-daily dosing (better compliance), no ototoxicity risk, stable antimicrobial susceptibility, lower contact dermatitis risk 6, 7, 9
  • Neomycin combinations advantages: Steroid component may hasten pain relief in some patients, generally lower cost 2, 7

When to Avoid Neomycin-Containing Preparations:

• History of contact dermatitis or sensitivity to topical antibiotics 1, 2
• Chronic or recurrent otitis externa (higher sensitization risk) 1
• Uncertain membrane integrity on examination 2
• Age <2 years (inadequate safety data) 4

Special Populations Requiring Modified Approach:

• Diabetes mellitus or immunocompromised: May require systemic antibiotics in addition to topical therapy; monitor closely for necrotizing otitis externa 2
• Prior radiotherapy: Consider systemic antibiotics; assess for modifying factors 2
• Suspected fungal co-infection: Avoid prolonged antibacterial therapy (>10 days); consider antifungal treatment 2, 10, 4

---

Critical Pitfalls to Avoid

• Using neomycin/polymyxin B preparations when membrane integrity cannot be confirmed - this risks permanent ototoxicity 2, 5, 7
• Failing to perform aural toilet before drop administration - debris prevents medication from reaching infected tissue 2
• Continuing treatment beyond 10 days - increases risk of fungal overgrowth (otomycosis) 10, 4
• Missing allergic contact dermatitis - presents as persistent erythema, pruritus, and otorrhea despite treatment; requires stopping the sensitizing agent 1, 2
• Prescribing oral antibiotics for uncomplicated cases - topical therapy achieves 100-1000 times higher drug concentrations and has superior outcomes 1, 2